论文部分内容阅读
目的 观察和评价含力克肺疾方案在耐多药结核病 (MDR TB)治疗中的疗效。方法 采用随机配对分组法将 62例MDR TB患者分为治疗组 (M组 ,31例 )和对照组 (C组 ,31例 )。化疗方案 :M组以力克肺疾为主 ,另依据药敏试验选用 3种以上敏感药或既往未用过的新药。C组不用力克肺疾 ,其它药物同M组。结果 治疗 9个月后 ,M组涂阳阴转率 61% ,培阳阴转率 65% ;C组涂阳阴转率2 9% ,培阳阴转率 32 %。痰菌阴转率M组显著高于C组 (P <0 .0 5)。M组病灶吸收及空洞关闭、缩小速度均显著高于C组 (P <0 .0 5)。 2年复查 ,M组和C组痰菌复阳率分别为 5%和 2 0 %。结论 含力克肺疾方案治疗MDR TB ,有助于痰菌阴转和病灶吸收好转 ,疗程结束后复发率低 ,疗效较为满意 ,值得临床上推广应用。
Objective To observe and evaluate the efficacy of Lectra Pulmonary Disease Program in the treatment of multidrug-resistant tuberculosis (MDR TB). Methods Sixty-two MDR TB patients were divided into treatment group (M group, 31 cases) and control group (C group, 31 cases) by random matching method. Chemotherapy: M group to Lectra lung disease-based, and the other based on susceptibility testing using more than three kinds of sensitive drugs or never used new drugs. C group did not force grams lung disease, other drugs with M group. Results After 9 months of treatment, the rate of smear-negative conversion in group M was 61% and that of culture-reform was 65%. In group C, the rate of smear-negative conversion was 29% and that of culture-reforming negative conversion rate was 32%. The sputum negative conversion rate in M group was significantly higher than that in C group (P <0.05). M group lesions absorption and hole closure, reduction rate were significantly higher than the C group (P <0.05). 2 years review, M group and C sputum bacilli rates were 5% and 20%. Conclusions The treatment of MDR TB with Lectra Pulmonary Disease regimen is conducive to the improvement of the sputum negative conversion and lesion absorption. The relapse rate is low after the end of treatment, and the curative effect is satisfactory, which is worth popularizing and applying clinically.